Kath Maitland

Last updated

Kathryn Maitland

Alma materSt Bartholomew’s Medical School
University of London
Scientific career
Institutions Imperial College, London
KEMRI-Wellcome Trust Research Programme, Kenya

Kathryn Maitland OBE FRCPCH FMedSci is a British paediatrician who is professor of infectious diseases at Imperial College London, director of the ICCARE Centre at the Institute of Global Health Innovation and an Honorary Fellow at Medical Research Council Clinical Trials Unit, University College, London. Since 2000 she has been based at the KEMRI-Wellcome Trust Research Programme, in Kilifi, Kenya. [1] [2]

Contents

Early life and education

Maitland attended school in Appleton, Cheshire. Maitland completed her undergraduate degree in medicine at the St Bartholomew’s Medical School in 1986. She specialises in paediatrics, global health and clinical trials. [3] [4]

Research and career

Maitland worked as a clinician scientist co-managing a project of field-based longitudinal epidemiology studies on the Pacific islands of Vanuatu, working with Professor Sir David Weatherall. The work investigated malaria parasite species interactions and host protection by alpha thalassaemia. [5] Since 2000, Maitland has been based full-time in East Africa, leading a research group studying the impact of effective emergency care on childhood mortality.

Maitland was the principal investigator on the FEAST trial. [6] The trial demonstrated that fluid boluses resulted in increased mortality in African children with severe febrile illness and excess mortality was largely a result of cardio-vascular collapse. The paper reporting the FEAST trial won the 2012 BMJ Research Paper of the Year. [7] Her group completed the multicentre TRACT trial which tested two transfusion [8] [9] and treatment strategies [10] in nearly 4000 children in Africa that aimed to reduce deaths and illness those hospitalised with severe anaemia, providing randomised evidence for transfusion management. Other aspects of her research portfolio include clinical studies and trials in severe malaria, [11] severe malnutrition and oxygen and respiratory support trial in children hospitalised with severe pneumonia. [12]

Maitland was elected to the Academy of Medical Sciences (United Kingdom) in 2016. [13] She was appointed Officer of the Order of the British Empire (OBE) in the 2022 Birthday Honours for services to medical science. [14]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Medical condition

Malaria is a mosquito-borne infectious disease that affects humans and other vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.

<span class="mw-page-title-main">Anemia</span> Medical condition

Anemia or anaemia is a blood disorder in which the blood has a reduced ability to carry oxygen due to a lower than normal number of red blood cells, or a reduction in the amount of hemoglobin. The name is derived from Ancient Greek: ἀναιμία anaimia, meaning 'lack of blood', from ἀν- an-, 'not' and αἷμα haima, 'blood'. When anemia comes on slowly, the symptoms are often vague, such as tiredness, weakness, shortness of breath, headaches, and a reduced ability to exercise. When anemia is acute, symptoms may include confusion, feeling like one is going to pass out, loss of consciousness, and increased thirst. Anemia must be significant before a person becomes noticeably pale. Symptoms of anemia depend on how quickly hemoglobin decreases. Additional symptoms may occur depending on the underlying cause. Preoperative anemia can increase the risk of needing a blood transfusion following surgery. Anemia can be temporary or long term and can range from mild to severe.

<span class="mw-page-title-main">Thalassemia</span> Medical condition

Thalassemias are inherited blood disorders that result in abnormal hemoglobin. Symptoms depend on the type of thalassemia and can vary from none to severe. Often there is mild to severe anemia as thalassemia can affect the production of red blood cells and also affect how long the red blood cells live. Symptoms of anemia include feeling tired and having pale skin. Other symptoms of thalassemia include bone problems, an enlarged spleen, yellowish skin, pulmonary hypertension, and dark urine. Slow growth may occur in children. Symptoms and presentations of thalassemia can change over time.

<span class="mw-page-title-main">Babesiosis</span> Malaria-like parasitic disease caused by infection with the alveoate Babesia or Theileria

Babesiosis or piroplasmosis is a malaria-like parasitic disease caused by infection with a eukaryotic parasite in the order Piroplasmida, typically a Babesia or Theileria, in the phylum Apicomplexa. Human babesiosis transmission via tick bite is most common in the Northeastern and Midwestern United States and parts of Europe, and sporadic throughout the rest of the world. It occurs in warm weather. People can get infected with Babesia parasites by the bite of an infected tick, by getting a blood transfusion from an infected donor of blood products, or by congenital transmission . Ticks transmit the human strain of babesiosis, so it often presents with other tick-borne illnesses such as Lyme disease. After trypanosomes, Babesia is thought to be the second-most common blood parasite of mammals. They can have major adverse effects on the health of domestic animals in areas without severe winters. In cattle the disease is known as Texas cattle fever or redwater.

<span class="mw-page-title-main">Acute respiratory distress syndrome</span> Human disease

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. Symptoms include shortness of breath (dyspnea), rapid breathing (tachypnea), and bluish skin coloration (cyanosis). For those who survive, a decreased quality of life is common.

<i>Plasmodium falciparum</i> Protozoan species of malaria parasite

Plasmodium falciparum is a unicellular protozoan parasite of humans, and the deadliest species of Plasmodium that causes malaria in humans. The parasite is transmitted through the bite of a female Anopheles mosquito and causes the disease's most dangerous form, falciparum malaria. It is responsible for around 50% of all malaria cases. P. falciparum is therefore regarded as the deadliest parasite in humans. It is also associated with the development of blood cancer and is classified as a Group 2A (probable) carcinogen.

<span class="mw-page-title-main">Hemolytic disease of the newborn</span> Fetal and neonatal alloimmune blood condition

Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis foetalis, is an alloimmune condition that develops in a fetus at or around birth, when the IgG molecules produced by the mother pass through the placenta. Among these antibodies are some which attack antigens on the red blood cells in the fetal circulation, breaking down and destroying the cells. The fetus can develop reticulocytosis and anemia. The intensity of this fetal disease ranges from mild to very severe, and fetal death from heart failure can occur. When the disease is moderate or severe, many erythroblasts are present in the fetal blood, earning these forms of the disease the name erythroblastosis fetalis.

<span class="mw-page-title-main">Artesunate</span> Chemical compound

Artesunate (AS) is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum.

<span class="mw-page-title-main">Atovaquone</span> Antimicrobial and antiprotozoan drug

Atovaquone, sold under the brand name Mepron, is an antimicrobial medication for the prevention and treatment of Pneumocystis jirovecii pneumonia (PCP).

Overdiagnosis is the diagnosis of disease that will never cause symptoms or death during a patient's ordinarily expected lifetime and thus presents no practical threat regardless of being pathologic. Overdiagnosis is a side effect of screening for early forms of disease. Although screening saves lives in some cases, in others it may turn people into patients unnecessarily and may lead to treatments that do no good and perhaps do harm. Given the tremendous variability that is normal in biology, it is inherent that the more one screens, the more incidental findings will generally be found. For a large percentage of them, the most appropriate medical response is to recognize them as something that does not require intervention; but determining which action a particular finding warrants can be very difficult, whether because the differential diagnosis is uncertain or because the risk ratio is uncertain.

<span class="mw-page-title-main">Beta thalassemia</span> Thalassemia characterized by the reduced or absent synthesis of the beta globin chains of hemoglobin

Beta thalassemias are a group of inherited blood disorders. They are forms of thalassemia caused by reduced or absent synthesis of the beta chains of hemoglobin that result in variable outcomes ranging from severe anemia to clinically asymptomatic individuals. Global annual incidence is estimated at one in 100,000. Beta thalassemias occur due to malfunctions in the hemoglobin subunit beta or HBB. The severity of the disease depends on the nature of the mutation.

Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology. Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.

Malaria prophylaxis is the preventive treatment of malaria. Several malaria vaccines are under development.

Malaria vaccines are vaccines that prevent malaria, a mosquito-borne infectious disease which annually affects an estimated 247 million people worldwide and causes 619,000 deaths. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

<span class="mw-page-title-main">Sickle cell disease</span> Group of genetic blood disorders

Sickle cell disease (SCD) is a group of blood disorders typically inherited. The most common type is known as sickle cell anaemia. It results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. This leads to a rigid, sickle-like shape under certain circumstances. Problems in sickle cell disease typically begin around 5 to 6 months of age. A number of health problems may develop, such as attacks of pain, anemia, swelling in the hands and feet, bacterial infections, and stroke. Long-term pain may develop as people get older. The average life expectancy in the developed world is 40 to 60 years.

Frederick Wabwire-Mangen is a Ugandan physician, public health specialist and medical researcher. Currently he is Professor of Epidemiology and Head of Department of Epidemiology & Biostatistics at Makerere University School of Public Health. Wabwire-Mangen also serves as the Chairman of Council of Kampala International University and a founding member of Accordia Global Health Foundation’s Academic Alliance

<span class="mw-page-title-main">RTS,S</span> Malaria vaccine

RTS,S/AS01 is a recombinant protein-based malaria vaccine. It is the only malaria vaccine approved and in wide use. As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

<span class="mw-page-title-main">Francis Omaswa</span> Ugandan cardiovascular surgeon, researcher and academic

Francis Gervase Omaswa, MBChB, MMed, FRCS (Edin), FCS (ECSA), is a Ugandan cardiovascular surgeon, academic and administrator. He was installed as the chancellor of Soroti University, one of the nine public universities in Uganda at that time, in August 2022.

Faith Hope Among’in Osier is a Kenyan immunologist, paediatrician and educator.

<span class="mw-page-title-main">John Crump</span> New Zealand-born infectious diseases physician, microbiologist, epidemiologist

John Andrew Crump MB ChB, MD, DTM&H, FRACP, FRCPA, FRCP is a New Zealand-born infectious diseases physician, medical microbiologist, and epidemiologist. He is Professor of Medicine, Pathology, and Global Health at the University of Otago and an adjunct professor of medicine, Pathology, and Global Health at Duke University. He served as inaugural co-director of the Otago Global Health Institute, one of the university's research centres. His primary research interest is fever in the tropics, focusing on invasive bacterial diseases and bacterial zoonoses.

References

  1. "Kathryn Maitland — CTMGH". www.tropicalmedicine.ox.ac.uk. Retrieved 17 June 2020.
  2. "Home - Professor Kath Maitland". www.imperial.ac.uk. Retrieved 17 June 2020.
  3. Kirby, Tony (1 December 2017). "Kathryn Maitland: asking the difficult questions". The Lancet Child & Adolescent Health. 1 (4): 262. doi:10.1016/S2352-4642(17)30075-5. ISSN   2352-4642.
  4. "Prof. Kathryn Maitland | Kemri | Wellcome Trust". kemri-wellcome.org. Retrieved 16 August 2022.
  5. Williams, T. N.; Maitland, K.; Bennett, S.; Ganczakowski, M.; Peto, T. E. A.; Newbold, C. I.; Bowden, D. K.; Weatherall, D. J.; Clegg, J. B. (October 1996). "High incidence of malaria in α-thalassaemic children". Nature. 383 (6600): 522–525. Bibcode:1996Natur.383..522W. doi:10.1038/383522a0. PMID   8849722. S2CID   4369124.
  6. "The FEAST Trial".
  7. Coombes, R. (29 May 2012). "Safer sport, shock treatment, stroke care, and safety triumph at the BMJ Group awards". BMJ. 344 (may29 1): e3741. doi:10.1136/bmj.e3741. PMID   22645213. S2CID   33535451.
  8. Maitland, Kathryn; Kiguli, Sarah; Opoka, Robert O.; Engoru, Charles; Olupot-Olupot, Peter; Akech, Samuel O.; Nyeko, Richard; Mtove, George; Reyburn, Hugh; Lang, Trudie; Brent, Bernadette; Evans, Jennifer A.; Tibenderana, James K.; Crawley, Jane; Russell, Elizabeth C.; Levin, Michael; Babiker, Abdel G.; Gibb, Diana M. (30 June 2011). "Mortality after Fluid Bolus in African Children with Severe Infection". New England Journal of Medicine. 364 (26): 2483–2495. doi:10.1056/NEJMoa1101549. hdl: 10044/1/20023 . PMID   21615299.
  9. Maitland, Kathryn; Kiguli, Sarah; Olupot-Olupot, Peter; Engoru, Charles; Mallewa, Macpherson; Saramago Goncalves, Pedro; Opoka, Robert O.; Mpoya, Ayub; Alaroker, Florence; Nteziyaremye, Julius; Chagaluka, George; Kennedy, Neil; Nabawanuka, Eva; Nakuya, Margaret; Namayanja, Cate; Uyoga, Sophie; Kyeyune Byabazaire, Dorothy; M’baya, Bridon; Wabwire, Benjamin; Frost, Gary; Bates, Imelda; Evans, Jennifer A.; Williams, Thomas N.; George, Elizabeth C.; Gibb, Diana M.; Walker, A. Sarah (1 August 2019). "Immediate Transfusion in African Children with Uncomplicated Severe Anemia". New England Journal of Medicine. 381 (5): 407–419. doi: 10.1056/NEJMoa1900105 . PMC   7611152 . PMID   31365799.
  10. Maitland, Kathryn; Olupot-Olupot, Peter; Kiguli, Sarah; Chagaluka, George; Alaroker, Florence; Opoka, Robert O; Mpoya, Ayub; Walsh, Kevin; Engoru, Charles; Nteziyaremye, Julius; Mallewa, Machpherson; Kennedy, Neil; Nakuya, Margaret; Namayanja, Cate; Kayaga, Julianne; Nabawanuka, Eva; Sennyondo, Tonny; Aromut, Denis; Kumwenda, Felistas; Musika, Cynthia Williams; Thomason, Margaret J; Bates, Imelda; von Hensbroek, Michael Boele; Evans, Jennifer A; Uyoga, Sophie; Williams, Thomas N; Frost, Gary; George, Elizabeth C; Gibb, Diana M; Walker, A Sarah (October 2019). "Co-trimoxazole or multivitamin multimineral supplement for post-discharge outcomes after severe anaemia in African children: a randomised controlled trial". The Lancet Global Health. 7 (10): e1435–e1447. doi: 10.1016/S2214-109X(19)30345-6 . PMC   7024999 . PMID   31537373.
  11. "Death Toll from Malaria among African children unacceptably high".
  12. Maitland, Kathryn; Kiguli, Sarah; Opoka, Robert O.; Olupot-Olupot, Peter; Engoru, Charles; Njuguna, Patricia; Bandika, Victor; Mpoya, Ayub; Bush, Andrew; Williams, Thomas N.; Grieve, Richard; Sadique, Zia; Fraser, John; Harrison, David; Rowan, Kathy (9 January 2018). "Children's Oxygen Administration Strategies Trial (COAST)".
  13. "Professor Kathryn Maitland | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 16 August 2022.
  14. "No. 63714". The London Gazette (Supplement). 1 June 2022. p. B14.

PubMed search for Kath Maitland